UroGen settles Jelmyto patent suit with Teva, generic entry set for September 2030

Filed June 2, 2026 · Period ending June 2, 2026 · ~1 min read

Key Changes

• high

  UroGen will allow Teva to launch generic Jelmyto on September 15, 2030, ending patent litigation and setting a firm date when generic competition will erode the company's market exclusivity for its key product.

  Item 8.01 verify on EDGAR →
• medium

  Settlement terminates all pending patent litigation in Delaware federal court, eliminating legal costs and uncertainty around Jelmyto's patent protection through 2030.

  Item 8.01 verify on EDGAR →
• low

  Agreement requires standard antitrust review by FTC and DOJ, though regulatory challenges to pharmaceutical patent settlements are uncommon.

  Item 8.01 verify on EDGAR →